View Future GrowthIndaptus Therapeutics 過去の業績過去 基準チェック /06Indaptus Therapeuticsの収益は年平均-22.5%で減少しているが、Biotechs業界はgrowingで30%年平均の収益となった。主要情報-22.53%収益成長率7.25%EPS成長率Biotechs 業界の成長17.04%収益成長率n/a株主資本利益率-661.54%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesNew major risk - Revenue and earnings growth May 03New major risk - Financial position Mar 18High number of new directors Mar 04Indaptus Therapeutics, Inc. Appoints David Natan as A Class II DirectorJan 09Less than half of directors are independent Jan 06Indaptus Therapeutics, Inc. Announces Resignations of Board Members Michael Newman, Mark Gilbert, and Anthony MaddalunaJan 03Forecast to breakeven in 2028 Dec 31Indaptus Therapeutics, Inc. announced that it expects to receive $6 million in fundingDec 24+ 1 more updateNew major risk - Financial position Nov 14Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.375 million.Sep 03New major risk - Financial position Aug 14Indaptus Therapeutics, Inc. announced that it has received $3.4 million in fundingJul 02Indaptus Therapeutics, Inc. announced that it has received $2.3 million in fundingJun 13Indaptus Therapeutics Doses First Patient in Phase 1B/2 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor TislelizumabJun 02New minor risk - Share price stability May 29New major risk - Financial position May 15Indaptus Therapeutics, Inc., Annual General Meeting, Jun 10, 2025Apr 19New major risk - Market cap size Mar 25Indaptus Therapeutics, Inc. Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20Mar 20Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor TislelizumabMar 18Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening Its Intellectual Property for Infectious Disease and Cancer TreatmentsMar 05Indaptus Therapeutics, Inc. announced that it expects to receive $20 million in funding from Yorkville Advisors Global LPFeb 13Indaptus Therapeutics, Inc. Receives Approval from Health Canada to Expand Clinical Trial of Decoy20Feb 05Indaptus Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price RequirementsFeb 02Indaptus Therapeutics, Inc. announced that it has received $2.246493 million in fundingJan 23New major risk - Shareholder dilution Jan 19Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in fundingJan 14New major risk - Market cap size Dec 05Insufficient new directors Dec 01Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.134995 million.Nov 23New major risk - Financial position Nov 14Indaptus Therapeutics, Inc. Presents Clinical Data on Decoy20 at SITC 2024 Annual MeetingNov 08Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety DataOct 16New minor risk - Shareholder dilution Aug 11Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.Aug 08Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.Aug 07+ 1 more updateIndaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20Jun 05Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20May 23Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?Mar 27New major risk - Financial position Mar 13New minor risk - Share price stability Mar 09Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 TrialMar 05Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20Nov 07Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20Sep 20Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?Aug 15Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20Aug 11Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023Aug 09Price target increased by 15% to US$15.00 Mar 19Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of DirectorsFeb 15Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid TumorsFeb 08Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid TumorsDec 14Price target decreased to US$11.00 Nov 16High number of new and inexperienced directors Nov 16Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45 Aug 08Indaptus Therapeutics, Inc., Annual General Meeting, Sep 29, 2022Aug 05CEO & Director recently bought US$52k worth of stock Jun 08Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid TumorsMay 20High number of new and inexperienced directors Apr 27High number of new and inexperienced directors Dec 31CEO & Director recently bought US$65k worth of stock Nov 21Insider recently bought US$691k worth of stock Oct 29Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications Sep 29CEO & Director recently bought US$84k worth of stock Sep 17収支内訳Indaptus Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:INDP 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-2110930 Sep 250-177930 Jun 250-177931 Mar 250-168831 Dec 240-158730 Sep 240-159730 Jun 240-169831 Mar 240-159731 Dec 230-159830 Sep 230-159730 Jun 230-159731 Mar 230-159731 Dec 220-149630 Sep 220-149530 Jun 220-149431 Mar 220-107331 Dec 210-85330 Sep 210-53230 Jun 210-31331 Mar 210-41331 Dec 200-413質の高い収益: INDPは現在利益が出ていません。利益率の向上: INDPは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: INDPは利益が出ておらず、過去 5 年間で損失は年間22.5%の割合で増加しています。成長の加速: INDPの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: INDPは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 40.2% ) と比較することは困難です。株主資本利益率高いROE: INDPは現在利益が出ていないため、自己資本利益率 ( -661.54% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 05:52終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Indaptus Therapeutics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jason McCarthyMaxim Group
Indaptus Therapeutics, Inc. Announces Resignations of Board Members Michael Newman, Mark Gilbert, and Anthony MaddalunaJan 03
Indaptus Therapeutics, Inc. announced that it expects to receive $6 million in fundingDec 24+ 1 more update
Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.375 million.Sep 03
Indaptus Therapeutics Doses First Patient in Phase 1B/2 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor TislelizumabJun 02
Indaptus Therapeutics, Inc. Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20Mar 20
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with Pd-1 Checkpoint Inhibitor TislelizumabMar 18
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening Its Intellectual Property for Infectious Disease and Cancer TreatmentsMar 05
Indaptus Therapeutics, Inc. announced that it expects to receive $20 million in funding from Yorkville Advisors Global LPFeb 13
Indaptus Therapeutics, Inc. Receives Approval from Health Canada to Expand Clinical Trial of Decoy20Feb 05
Indaptus Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price RequirementsFeb 02
Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.134995 million.Nov 23
Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety DataOct 16
Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.Aug 08
Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.Aug 07+ 1 more update
Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20May 23
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20Nov 07
Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20Sep 20
Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20Aug 11
Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023Aug 09
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid TumorsFeb 08
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid TumorsDec 14
Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid TumorsMay 20
